Oblimersen Sodium and Rituximab in Treating Patients With Recurrent B-cell Non-Hodgkin Lymphoma

Inclusion Criteria

• •Must have recurrent B-cell NHL and measurable disease
• •No anti-lymphoma therapy within the past 4 weeks
• •Must have a good performance status (less than or equal to 2 Zubrod, greater than or equal to 60 Karnofsky)
• •Absolute neutrophil count (ANC) greater than or equal to 1,000
• •Platelets greater than or equal to 75,000
• •Hemoglobin greater than or equal to 10 g/dL
• •Bilirubin less than or equal to 1.5 mg/dL
• •Serum glutamic oxaloacetic transaminase (SGOT), serum glutamic pyruvate transaminase (SGPT) less than or equal to 2 times upper limit of laboratory normals
• •Alkaline phosphatase less than or equal to 2 times upper limit of laboratory normals
• •Serum creatinine less than or equal to 1.8 mg/dL
• •Must sign a consent form, and must have a life expectancy of greater than 12 weeks
• •No more than 3 prior chemotherapy regimens
• •Patients who are either Rituximab naive, have previously responded to Rituximab, or are refractory to Rituximab used alone or in combination with chemotherapy